Safety and Efficacy of LEO 80185 Topical Suspension in Adolescent Subjects (Aged 12 to 17) With Scalp Psoriasis
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of once daily use of LEO
80185 topical suspension in adolescent subjects (aged 12 to 17 years) with scalp psoriasis.
LEO 80185 topical suspension has marketing approval in many countries under the brand names
Taclonex Scalp® Topical Suspension and Xamiol® gel for the treatment of scalp psoriasis in
adults. No studies have been performed in subjects younger than 18 years.